Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Indian scientists: We didn't back doubling of vaccine dosing gap

06/15/2021 | 12:52pm EDT

NEW DELHI, June 15 (Reuters) - The Indian government doubled the gap between the two doses of the AstraZeneca COVID-19 vaccine without the agreement of the scientific group that it said recommended the increase, three members of the advisory body told Reuters.

The ministry of health announced the decision to change the gap from 6-8 weeks to 12-16 weeks on May 13, at a time when supplies of the shot were falling short of demand and infections were surging across the country.

It said the extended gap was recommended by the National Technical Advisory Group on Immunisation (NTAGI), based on real-life evidence mainly from Britain. Yet the NTAGI scientists, classified by the government as three of the 14 "core members", said the body did not have enough data to make such a recommendation.

M.D. Gupte, a former director of the state-run National Institute of Epidemiology, said the NTAGI had backed increasing the dosing interval to 8-12 weeks - the gap advised by the World Health Organization. But he added that the group had no data concerning the effects of a gap beyond 12 weeks.

"Eight to 12 weeks is something we all accepted, 12 to 16 weeks is something the government has come out with," he added. "This may be alright, may not be. We have no information on that."

This was echoed by his NTAGI colleague Mathew Varghese, who said the group's recommendation was only for 8-12 weeks.

The health ministry, citing the head of NTAGI's working group on COVID-19, said that the dosing decision was based on scientific evidence. "There was no dissenting voices among the NTAGI members," the ministry said on Twitter.

The ministry's statement https://pib.gov.in/PressReleasePage.aspx?PRID=1718308 on May 13 said that it had accepted the 12-16 weeks recommendation from NTAGI's COVID working group, as had a group of mainly government officials tasked with vaccine administration, known as NEGVAC.

Government health officials told a news conference on May 15 the gap was not increased to address a vaccine shortage but was a "scientific decision".

J.P. Muliyil, a member of the seven-strong COVID working group, said there had been discussions within the NTAGI on increasing the vaccine dosage interval but that the body had not recommended 12-16 weeks.

"That specific number was not quoted," he said, without elaborating.

N.K. Arora, the COVID working group head, declined to comment to Reuters on its recommendations but said all its decisions were taken collectively by the NTAGI at large.

A NEGVAC representative said it "respects the decisions of the NTAGI and use them for our work", declining to elaborate.

Real-world data released early last month by South Korea showed https://www.reuters.com/world/asia-pacific/skorea-says-astrazeneca-pfizer-covid-19-vaccines-87-effective-after-first-shot-2021-05-05 that one dose of the vaccines from AstraZeneca and Pfizer was 86.6% effective in preventing infections among people aged 60 and older.

Muliyil said this increased confidence within the advisory body that delaying a second shot would not be harmful.

The AstraZeneca vaccine accounts for nearly 90% of the 257.5 million vaccine doses administered in India.

The dispute over doses comes amid criticism from some scientists that the government had been slow to respond to a new virus variant that led to a spike in infections in April and May.

The government has denied being slow to react, saying state-run laboratories had studied variants in real time and shared data with local authorities to allow them to take the necessary action.

Shahid Jameel, a top Indian virologist who recently quit a government panel on virus variants after criticising New Delhi over its response to the pandemic, said the authorities should clarify their position on the reasons for the decision to double the gap between doses.

"In a situation where we have a variant of concern spreading, we should really be vaccinating people at scale and making sure that they are protected," he added. (Reporting by Krishna N. Das and Devjyot Ghoshal; Editing by Sanjeev Miglani and Pravin Char)

© Reuters 2021
All news about ASTRAZENECA PLC
11:43aASTRAZENECA : H1 2021 results
11:43aASTRAZENECA : NHS - Presidential visit strengthens healthcare partnership with K..
10:42aASTRAZENECA : US authorities probing Emergent BioSolutions over COVID-19 vaccine..
09:06aASTRAZENECA : Shortages Hamper Ohangwena Vaccination Drive
06:47aASTRAZENECA : Receives a Buy rating from Credit Suisse
07/29ASTRAZENECA : Emergent to resume J&J COVID-19 vaccine production at Baltimore pl..
07/29Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - exe..
07/29AstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges
07/29ASTRAZENECA : to seek US approval of COVID vaccine in 2nd half
07/29ASTRAZENECA : COVID-19 Jabs Supplied to Canada, Mexico From US Before Inspection..
More news
Financials (USD)
Sales 2021 34 470 M - -
Net income 2021 5 907 M - -
Net Debt 2021 26 467 M - -
P/E ratio 2021 30,5x
Yield 2021 2,44%
Capitalization 179 B 179 B -
EV / Sales 2021 5,96x
EV / Sales 2022 4,77x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 115,58 $
Average target price 133,66 $
Spread / Average Target 15,6%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.01%179 111
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%335 069
PFIZER, INC.16.25%239 525
NOVARTIS AG-0.16%224 495